These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 263873)
41. Rubini, a new live attenuated mumps vaccine virus strain for human diploid cells. Glück R; Hoskins JM; Wegmann A; Just M; Germanier R Dev Biol Stand; 1986; 65():29-35. PubMed ID: 3556774 [TBL] [Abstract][Full Text] [Related]
42. [Immunity to measles, mumps and rubella in children vaccinated with triple viral vaccine]. Pisón Garcés FJ; Galbe Sánchez-Ventura J; Arcauz Eguren P; Aguirre y Dabán C; Mengual Gil J; Larrad Mur L Aten Primaria; 1995 Mar; 15(4):235-7. PubMed ID: 7703334 [TBL] [Abstract][Full Text] [Related]
43. Combined trivalent and bivalent measles, mumps and rubella virus vaccination. A controlled trial. Swartz TA; Klingberg W; Klingberg MA Infection; 1974; 2(3):115-7. PubMed ID: 4606362 [No Abstract] [Full Text] [Related]
44. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group. White CJ; Stinson D; Staehle B; Cho I; Matthews H; Ngai A; Keller P; Eiden J; Kuter B Clin Infect Dis; 1997 May; 24(5):925-31. PubMed ID: 9142794 [TBL] [Abstract][Full Text] [Related]
45. Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response. Nakayama T; Urano T; Osano M; Nakagawa M; Maehara N; Sasaki K; Yamamura AM; Makino S Microbiol Immunol; 1990; 34(6):497-508. PubMed ID: 2120551 [TBL] [Abstract][Full Text] [Related]
46. Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. Weibel RE; Carlson AJ; Villarejos VM; Buynak EB; McLean AA; Hilleman MR Proc Soc Exp Biol Med; 1980 Nov; 165(2):323-6. PubMed ID: 7443721 [No Abstract] [Full Text] [Related]
47. Clinical trial of a new trivalent measles-mumps-rubella vaccine in young children. Vesikari T; Ala-Laurila EL; Heikkinen A; Terho A; D'Hondt E; André FE Am J Dis Child; 1984 Sep; 138(9):843-7. PubMed ID: 6383020 [TBL] [Abstract][Full Text] [Related]
49. Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule. Christenson B; Böttiger M Vaccine; 1991 May; 9(5):326-9. PubMed ID: 1872016 [TBL] [Abstract][Full Text] [Related]
50. Interference between strains in live virus vaccines, I: Combined vaccination with measles, mumps and rubella vaccine. Berger R; Just M; Glück R J Biol Stand; 1988 Oct; 16(4):269-73. PubMed ID: 3198657 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. Ljungman P; Fridell E; Lönnqvist B; Bolme P; Böttiger M; Gahrton G; Linde A; Ringdén O; Wahren B J Infect Dis; 1989 Apr; 159(4):610-5. PubMed ID: 2647859 [TBL] [Abstract][Full Text] [Related]
52. Serologic responses to measles, mumps, and rubella (MMR) vaccine in healthy infants: failure to respond to measles and mumps components may influence decisions on timing of the second dose of MMR. Mitchell LA; Tingle AJ; Décarie D; Lajeunesse C Can J Public Health; 1998; 89(5):325-8. PubMed ID: 9813922 [TBL] [Abstract][Full Text] [Related]
53. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland. Davidkin I; Peltola H; Leinikki P; Valle M Vaccine; 2000 Jul; 18(27):3106-12. PubMed ID: 10856790 [TBL] [Abstract][Full Text] [Related]
54. Clinical evaluation of a new measles-mumps-rubella trivalent vaccine. Schwarz AJ; Jackson JE; Ehrenkranz NJ; Ventura A; Schiff GM; Walters VW Am J Dis Child; 1975 Dec; 129(12):1408-12. PubMed ID: 128287 [TBL] [Abstract][Full Text] [Related]
55. Follow-up surveillance for antibody in human subjects following live attenuated measles, mumps, and rubella virus vaccines. Weibel RE; Buynak EB; McLean AA; Hilleman MR Proc Soc Exp Biol Med; 1979 Nov; 162(2):328-32. PubMed ID: 515009 [No Abstract] [Full Text] [Related]
56. Interference between strains in live virus vaccines. II: Combined vaccination with varicella and measles-mumps-rubella vaccine. Berger R; Just M J Biol Stand; 1988 Oct; 16(4):275-9. PubMed ID: 2848843 [TBL] [Abstract][Full Text] [Related]
57. Comparison of the Urabe Am 9-Schwarz and Jeryl Lynn-Moraten combinations of mumps-measles vaccines in young children. Vesikari T; André FE; Simoen E; Florent G; Ala-Laurila EL; Heikkinen A; Kuusinen H; Terho A Acta Paediatr Scand; 1983 Jan; 72(1):41-6. PubMed ID: 6344551 [TBL] [Abstract][Full Text] [Related]
58. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046 [TBL] [Abstract][Full Text] [Related]
59. Expanded programme on immunization. Vaccine efficacy in a measles immunization programme. Wkly Epidemiol Rec; 1992 Jul; 67(30):224-7. PubMed ID: 1498025 [No Abstract] [Full Text] [Related]
60. Vaccination against measles, mumps and rubella (MMR): a comparison between the antibody responses at the ages of 18 months and 12 years and between different methods of antibody titration. Christenson B; Böttiger M J Biol Stand; 1985 Apr; 13(2):167-72. PubMed ID: 3997899 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]